Chiome Bioscience Full Year 2024 Earnings: JP¥17.54 loss per share (vs JP¥24.62 loss in FY 2023)

Chiome Bioscience (TSE:4583) Full Year 2024 Results

Key Financial Results

• Revenue: JP¥780.8m (up 14% from FY 2023).
• Net loss: JP¥1.02b (loss narrowed by 16% from FY 2023).
• JP¥17.54 loss per share (improved from JP¥24.62 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Drug Discovery Support segment contributing a total revenue of JP¥577.9m (74% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to JP¥936.7m (64% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of JP¥10.1m. Explore how 4583's revenue and expenses shape its earnings.

Chiome Bioscience shares are down 22% from a week ago.

Risk Analysis

Before you take the next step you should know about the 3 warning signs for Chiome Bioscience (1 is potentially serious!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.